Brief: Altamira Therapeutics’ Semaphore Delivery Platform Shows Significant Synergis-Tic Effects Of Zbtb46 Mrna With Pd1 Immunotherapy In Control Of Tumor Growth In Animal Model
22/03/2023 12:54
March 22 (Reuters) - Altamira Therapeutics Ltd CYTO.O :
* ALTAMIRA THERAPEUTICS’ SEMAPHORE DELIVERY PLATFORM SHOWS
SIGNIFICANT SYNERGIS-TIC EFFECTS OF ZBTB46 MRNA WITH PD1
IMMUNOTHERAPY IN CONTROL OF TUMOR GROWTH IN ANIMAL MODEL
* ALTAMIRA THERAPEUTICS LTD - NANOPARTICLE TREATMENT
COMBINED WITH
IMMUNE CHECKPOINT INHIBITOR RESULTS IN SYNERGISTIC CONTROL OF
TUMOR GROWTH
Source text for Eikon: ID:nGNXbw8QPQ
Further company coverage: CYTO.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Altamira Therapeutics
See all newsBrief: Altamira Therapeutics Reports Full Year 2024 Results
Brief: Altamira Therapeutics Announces Transition From Nasdaq To OTC Markets
Brief: Altamira Therapeutics Provides Update On Nasdaq Listing
Brief: Altamira Therapeutics Provides Business Update And First Half 2024 Financial Results
Brief: Altamira Therapeutics Announces Pricing Of Up To $12.0 Mln Public Offering